Trial Profile

A 12-Month Open-Label, Repeat-Dose Safety Study of NRL-1 in Epilepsy Subjects (DIAZ.001.05)

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 15 Apr 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Diazepam (Primary) ; Benzodiazepines
Indications Epilepsy; Generalised epilepsy; Partial epilepsies; Seizures
Focus Registrational; Therapeutic Use
Sponsors Neurelis

Most Recent Events

11 Apr 2024 According to a Neurelis Media Release, post-hoc analysis data from this study will be presented at the 76th Annual Meeting of the American Academy of Neurology (AAN) in Denver from April 13 to 18.
04 Jan 2024 Results of exploratory Post Hoc analysis assessing effect of timing of rescue therapy administration for seizure clusters in epilepsy , published in the Neurology and Therapy
01 Dec 2023 Results presented in a Neurelis Media Release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com